- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00991393
Sinus Augmentation With Dental Implant (SinusDI)
An Open Label, Non Randomized, Single Arm, Multi Center Study to Assess Sinus Augmentation (Sinus Lift) Utilizing INFUSE® Bone Graft Concurrent With Dental Implant Placement
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The INFUSE® Bone Graft is a device approved by the FDA to be used instead of using your own bone (from another site on your body) to replace missing bone in your jaw. INFUSE® Bone Graft is commercially available and is made up of 2 parts - recombinant human Bone Morphogenetic Protein-2 (rhBMP 2) placed on an absorbable collagen sponge (ACS). The rhBMP-2 is a genetically altered protein which recruits bone-forming cells to the surgical area and changes local cells to bone. ACS is made from Type I collagen from bovine (cattle) tendon. It helps to hold the rhBMP-2 in place and acts as a support for the growing bone. The sponge itself will reabsorb in time as the new bone forms.
The purpose of this research study is to shorten the treatment time course for the patients. This post-market study has been designed to further evaluate the effectiveness and safety of INFUSE® Bone Graft, along with dental implant placement and a sinus lift, in a single procedure.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
California
-
Fullerton, California, United States, 92835
-
-
North Carolina
-
Denver, North Carolina, United States, 28037
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
-
-
Texas
-
Dallas, Texas, United States, 75246
-
Houston, Texas, United States, 77063
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Able to provide written informed consent
- ≥ 18 years
- Requires and receives sinus augmentation as part of the scheduled dental implantation into the maxillary alveolar ridge
- Negative urine pregnancy test for patients of child bearing potential and agreement to not become pregnant for at least 12 months after surgery
- Able to comply with all study-related procedures, including exercising good oral hygiene
- A prosthodontic treatment plan has been drafted.
Exclusion Criteria:
- Known hypersensitivity to rhBMP-2, bovine Type I collagen or other components of the formulation
- Known hypersensitivity to titanium
- Operative site is in the area of a resected or extant tumor
- Any active malignancy or current treatment for a malignancy
- Active infection at operative site
- History of prior exposure to rhBMP-2/ACS
- Received and failed a previous sinus augmentation procedure
- Pathology that would either compromise a bone grafting procedure, or interfere with obtaining quantitative measurements from postoperative computer tomography scans
- Significant untreated periodontal disease (> Grade 3), caries, or chronic inflammation of the oral cavity at operative site
- Active use of any nicotine-containing products such as, but not limited to, smoking and chewing tobacco, nicotine patch, nicotine gum, etc.
- Insulin-dependent diabetic, or has known HgbA1c levels >6.5 %
- History of malignancy within the past 5 years except for basal cell or squamous cell carcinoma of the skin
- Patients who are lactating
- History of metabolic bone disease, excluding idiopathic osteoporosis
- History of autoimmune disease (e.g., documented multiple allergies, systemic lupus erythematosus, dermatomyositis, etc.) or immunosuppressive disease (e.g, Human Immunodeficiency Virus or Acquired Immune Deficiency Syndrome)
- History of immune deficiency due to other treatments (e.g., radiation therapy, chemotherapy, steroid therapy)
- History of adverse reaction to prior exposure to silicone or injectable collagen
- Treatment with an investigational therapy within 1 month before the surgical procedure or plans to be treated with an investigational therapy during the study period.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
INFUSE® Bone Graft
all study participants will receive INFUSE® Bone Graft
|
Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS in the area of the dental implant on Day 0 (Surgery).
A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as the standard of care (SOC) for the facility.
Patients will return to the facility for final End of Study (EOS) assessments 6 months after surgery for placement of the appropriate prosthetic, and assessment of osseointegration and stability.
Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinical stability and osseointegration of endosseous dental implants
Time Frame: 6 months post-implantation
|
6 months post-implantation
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evidence of successful INFUSE® Bone Graft placement, as well as the safety of INFUSE® when used in sinus augmentation which will be confirmed by CT scans.
Time Frame: 6 months post-implantation
|
6 months post-implantation
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- P09-05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Maxillary Sinus Bone Loss
-
Cairo UniversityCompletedDental Implant | Maxillary Sinus | Maxillary Sinus Lift | Maxillary Sinus ElevationEgypt
-
Tufts UniversityNot yet recruitingDental Implant | Bone Substitute | Maxillary Sinus Floor Augmentation | Autogenous Bone GraftUnited States
-
Mashhad University of Medical SciencesCompletedDisorder of Maxillary Sinus | Maxillary Sinus Floor AugmentationIran, Islamic Republic of
-
Postgraduate Institute of Dental Sciences RohtakUnknownPeriodontal Bone Loss | Maxillary Sinus DiseaseIndia
-
The Dental Hospital of Zhejiang University School...RecruitingSinus Floor Augmentation | Maxillary SinusChina
-
University of MinnesotaNovaBone Products, LLCCompletedSinus Floor Augmentation | Maxillary SinusUnited States
-
Kırıkkale UniversityCompleted
-
Cairo UniversityUnknown
-
University of Sao PauloCompleted
-
Cairo UniversityUnknownMaxillary Sinus
Clinical Trials on INFUSE® Bone Graft
-
Medtronic Spinal and BiologicsAverion International CorporationTerminatedAlveolar Bone LossUnited States
-
Medtronic Spinal and BiologicsAverion International CorporationTerminatedAlveolar Bone LossUnited States
-
Medtronic Spinal and BiologicsAverion International Corporation; Baim Institute for Clinical ResearchWithdrawnAlveolar Bone Loss in Mandible | Edentulous Alveolar Ridge In Mandible
-
Medtronic Spinal and BiologicsTerminated
-
Medtronic Spinal and BiologicsCompleted
-
Medtronic Spinal and BiologicsRecruitingIntervertebral Disc Degeneration | Spinal Fusion | Lumbar Disc DiseaseKorea, Republic of
-
Medtronic Spinal and BiologicsRecruitingMulti-Level Degenerative Lumbosacral Spinal ConditionsUnited States
-
Medtronic Spinal and BiologicsCompletedDegenerative Disc DiseaseUnited States
-
Medtronic Spinal and BiologicsTerminatedLumbar Spine DegenerationUnited States
-
Medtronic Spinal and BiologicsCompletedDegenerative Disc Disease